If you have been reading about Melanotan II and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-21. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
=== Meckel's diverticulum === Pertechnetate is actively accumulated and secreted by the mucoid cells of the gastric mucosa, and therefore, technetate(VII) radiolabeled with Tc99m is injected into the body when looking for ectopic gastric tissue as is found in a Meckel's diverticulum with Meckel's Scans.
Venlafaxine has been implicated in causing the most severe withdrawal symptoms after cessation of use, possibly due to its short half-life. To simplify identifying the principal signs and symptoms, the mnemonic FINISH may be used:
In addition to these shared features, comparative studies have identified metabolic and immunoregulatory traits that distinguish S. boulardii from many other S. cerevisiae strains and may contribute to its probiotic activity. These include elevated production of acetate and succinate under aerobic conditions, enhanced anti-inflammatory effects in cell-based models, and selective activation of the aryl hydrocarbon receptor (AhR), a key regulator of intestinal immune homeostasis. S. boulardii also encodes additional copies of flocculin genes, which may promote interactions with bacterial pathogens and reduce their adherence to the intestinal mucus layer. S. boulardii produces high amounts of the short-chain fatty acid acetic acid (acetate). This results in S. boulardii increasing acidity and having strong antibacterial properties. It also shows anti-inflammatory effects and can increase beneficial gut bacteria such as Akkermansiaceae and Bifidobacteriaceae via symbiotic mechanisms in preclinical research. The yeast has also been found to reverse antibiotic-induced gut dysbiosis in rodents, including restoring beneficial bacteria such as Lactobacillus, Bifidobacterium, Firmicutes, and Clostridium. This was associated with reduced neuroinflammation and related behavioral changes.
Sources: en.wikipedia.org
== Uses == PET is both a medical and research tool used in pre-clinical and clinical settings. It is used heavily in the imaging of tumors and the search for metastases within the field of clinical oncology, and for the clinical diagnosis of certain diffuse brain diseases such as those causing various types of dementias. PET is valued as a research tool to learn and enhance knowledge of the normal human brain, heart function, and support drug development. PET is also used in pre-clinical studies using animals. It allows repeated investigations into the same subjects over time, where subjects can act as their own control and substantially reduces the numbers of animals required for a given study. This approach allows research studies to reduce the sample size needed while increasing the statistical quality of its results. Physiological processes result in anatomical changes within the body. Because PET can detect biochemical activity and the expression of certain proteins, it can provide molecular-level information long before any anatomical alterations become visible. PET achieves this by using radiolabelled molecular probes, which are taken up at varying rates depending on the tissue. Regional tracer uptake in different anatomical structures can then be visualized and approximately quantified based on the amount of injected positron-emitting tracer detected in the scan, via metrics like the standardized uptake value. It is possible to acquire PET images using a conventional dual-head gamma camera fitted with a coincidence detector.
Sharpey's fibres (bone fibres, or perforating fibres) are a matrix of connective tissue consisting of bundles of strong predominantly type I collagen fibres connecting periosteum to bone. They are part of the outer fibrous layer of periosteum, entering into the outer circumferential and interstitial lamellae of bone tissue. Sharpey's fibres also attach muscle to the periosteum of bone by merging with the fibrous periosteum and underlying bone as well. A good example is the attachment of the rotator cuff muscles to the blade of the scapula. In the teeth, Sharpey's fibres are the terminal ends of principal fibres (of the periodontal ligament) that insert into the cementum and into the periosteum of the alveolar bone. A study on rats suggests that the three-dimensional structure of Sharpey's fibres intensifies the continuity between the periodontal ligament fibre and the alveolar bone (tooth socket), and acts as a buffer medium against stress. Sharpey's fibres in the primary acellular cementum are mineralized fully; those in cellular cementum and bone are mineralized only partially at their periphery. In the skull, the main function of Sharpey's fibres is to bind the cranial bones in a firm but moveable manner; they are most numerous in areas where the bones are subjected to the greatest forces of separation. In the spine, similar fibres join the intervertebral disc to the adjacent vertebrae. Each fibre is accompanied by an arteriole and one or more nerve fibres.
== History == Vertex Pharmaceuticals announced in January 2024 that suzetrigine had successfully met several endpoints in its phase III clinical trials. The company announced in July 2024 that the US Food and Drug Administration (FDA) had accepted a New Drug Application for suzetrigine. Due to its novel mechanism, the FDA granted priority review, fast track, and breakthrough therapy designations to the application for suzetrigine. In January 2025, the FDA granted approval of Journavx to Vertex Pharmaceuticals, making it the first non-opioid pain medication to be approved by the FDA in two decades. As of November 2025, phase IV post-marketing clinical trials are underway to assess the effectiveness and safety of suzetrigine as a part of multimodal therapy for the treatment of acute post-operative pain. The manufacturer engaged in lobbying activity promoting non-opioid pain treatment and supporting the NO PAIN Act (Non-Opioids Prevent Addiction In the Nation Act).
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.